World Cancer Day - 4 Feb
This World Cancer Day we are proud to be featured in ITN's programme - Working Together: To Tackle Cancer. Alongside other leading organisations including Cancer Research UK, we discuss the importance of accurate diagnostics in the ever-evolving world of Cancer treatment.
What have we been up to in January?
Happy new year! We got 2023 off to a great start with our MammaTyper® International Distributor Meeting on 12th and 13th of January in Venice. Our distributors brought a wealth of clinical and technical expertise from the UK, Italy, Switzerland, Turkey, Czech Republic, Romania, Israel and Greece. Our community benefitted from pathology and oncology talks from eminent clinicians, who presented the latest updates to the MammaTyper® evidence-base. Professor Abeer Shaaban attended the day: find out more about her work in breast pathology on our blog.
Interview: Professor Abeer Shaaban: consultant breast pathologist
Professor Abeer Shaaban is a specialist consultant breast pathologist at Queen Elizabeth Hospital Birmingham and Honorary Professor at the University of Birmingham. She has led a number of research studies and contributed to landmark breast cancer trials. Dr Shaaban recently led a study with a team of researchers from the UK and Egypt comparing MammaTyper® ® RT-qPCR and immunohistochemistry (IHC) assessment on needle core biopsies of breast cancer. We spoke to Professor Shaaban about her life-saving work and her role in this piece of research.
Stage 4 breast cancer: treatment advances
Stage 4 breast cancer is also known as metastatic breast cancer, secondary breast cancer or advanced breast cancer. All these terms cover cases where the cancer has metastasized from the breast to other regions of the body. Most commonly the lymph nodes, bone, liver, lungs and brain. Signs of metastatic breast cancer depend on the site of spread
New multigene breast cancer test could speed up accurate diagnosis for women, evidence suggests
Every breast cancer tumour is unique. Accurate subtyping of breast cancer tumors is essential to determine the type of treatment that the disease is likely to respond to. This has become especially important in hard to diagnose triple negative and HER2-low cases where new immunotherapy drugs have been recently approved for use.
Treatment for triple-negative breast cancer will now be available for patients in England
The rapid diagnosis, subtyping and identification of tumours, including those that are triple-negative, is key to the fight against breast cancer.
Low HER2 breast cancer: progress in treatment needs progress in diagnostics.
Improving accurate detection of low HER-2 breast cancers.
Cerca Biotech
Cerca Biotech is the European subsidiary of Shuwen Biotech, who you might already recognise as being a highly reputable and innovative molecular and point of care diagnostics organisation.
MammaTyper® is a new tool for subtyping breast cancer.
READ MORE +
A rapid, simple, Point Of Care screening test for urinary congophilia.
READ MORE +ABOUT US
Cerca Biotech
Cerca Biotech is the European subsidiary of Shuwen Biotech, a highly reputable and innovative molecular and point of care diagnostics organisation. Shuwen and Cerca are passionate about healthcare and are working to create world-leading innovations in the fields of Oncology and Women’s Health.
High-performance test
Quantitative RT-qPCR assay (CE marked IVD)
- Highly reproducible biomarker assessment
- Reliable results through standardized biomarker detection
- Accurate stratification of breast cancer tumors into St Gallen subtypes
Promising clinical utility
Clinical value validated in numerous performance evaluation studies
- Outperforms IHC by accurate Ki-67 determination
- Provides information on patient‘s prognosis
- Accurate subtyping supports treatment decisions
Easy-to-use
Clinical value validated in numerous performance evaluation studies
- Reliable method for any molecular pathology laboratory
- Validated for multiple qPCR instruments*
- From resection or core needle biopsy FFPE sample to result within 6 hours FFPE = formalin fixed paraffin embedded
NEWS
Recent article and news
What have we been up to in January?
We got 2023 off to a great start with our MammaTyper® International Distributor Meeting on 12th and 13th of January in Venice. Our distributors brought a wealth of clinical and technical expertise from the UK, Italy, Switzerland, Turkey, Czech Republic, Romania, Israel and Greece. Our community benefitted from pathology and oncology talks from eminent clinicians, who presented the latest updates to the MammaTyper® evidence-base. Professor Abeer Shaaban attended the day: find out more about her work in breast pathology on our blog.
Interview: Professor Abeer Shaaban: consultant breast pathologist
Professor Abeer Shaaban is a specialist consultant breast pathologist at Queen Elizabeth Hospital Birmingham and Honorary Professor at the University of Birmingham. She has led a number of research studies and contributed to landmark breast cancer trials. Dr Shaaban recently led a study with a team of researchers from the UK and Egypt comparing MammaTyper® ® RT-qPCR and immunohistochemistry (IHC) assessment on needle core biopsies of breast cancer. We spoke to Professor Shaaban about her life-saving work and her role in this piece of research.
Stage 4 breast cancer: treatment advances
Breast cancer tissue is assessed at diagnosis to determine treatment approach and prognosis. Whilst stage 4 or metastatic breast cancer is classed as incurable, treatment options that can prolong life are becoming available. However, we need to ensure that diagnostic technology used in labs keeps pace with advances in treatment, so that those with this late-stage cancer can access these innovative therapies